13710-19-5 Usage
Chemical Properties
White Solid
Uses
Different sources of media describe the Uses of 13710-19-5 differently. You can refer to the following data:
1. antiinflammatory, analgesia
2. Amidated GRF fragment equipotent to GRF in release of somatotropin from anterior pituitary
3. A non steroidal anti-inflammatory agent found to inhibit COX-2 isoenzymes
4. Tolfenamic acid is a non-steroidal anti-inflammatory agent. It interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor. It inhibits fMLP- and A23187-induced Ca2+ influx in human PMNL with an IC50 value of approximately 20 μM.
5. Non-steroidal anti-inflammatory drugs (NSAIDs).
Definition
ChEBI: An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity.
General Description
Tolfenamic Acid is an anthranilic acid derivative and a non-steroidal anti-inflammatory drug (NSAID). Its applications in treating pancreatic, esophageal, colorectal and lung cancer is being investigated.
Biochem/physiol Actions
Non-steroidal anti-inflammatory agent. Interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor.
Clinical Use
NSAID: Treatment of migraine
Veterinary Drugs and Treatments
Tolfenamic acid may be useful for the treatment of acute or chronic
pain and/or inflammation in dogs and acute pain/inflammation in
cats. In Europe, it is also approved for use in cattle.
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlafaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity
Metabolism
Tolfenamic acid is metabolised in the liver; the metabolites and unchanged drug are conjugated with glucuronic acid. About 90% of an ingested dose is excreted in the urine and the remainder in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 13710-19-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,7,1 and 0 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 13710-19:
(7*1)+(6*3)+(5*7)+(4*1)+(3*0)+(2*1)+(1*9)=75
75 % 10 = 5
So 13710-19-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
13710-19-5Relevant articles and documents
Anti-inflammatory, antiproliferative, and radical-scavenging activities of tolfenamic acid and its metal complexes
Kovala-Demertzi, Dimitra,Hadjipavlou-Litin, Dimitra,Primikiri, Alexandra,Staninska, Malgorzata,Kotoglou, Chronis,Demertzis, Mavroudis A.
, p. 948 - 960 (2009)
Some new complexes of tolfenamic acid (=2-[(2-methyl-3-chlorophenyl)amino] benzoic acid; Htolf) with potentially interesting biological activities are described. The complexes [Mn(tolf)2(H2O)2], [Co(tolf)2(H2O)2], [Ni(tolf2(H 2O)2], [Cu(tolf)2(H2O)]2 , and [Zn(tolf)2(H2O)] were prepared by the reaction of tolfenamic acid, a potent anti-inflammatory drug, with metal salts. The radical-scavenging activities of the complexes were evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical-scavenging assay. Their ability to inhibit soybean lipoxygenase, β-glucuronidase, and trypsin-induced proteolysis was studied. Their inhibitory effects on rat paw edema induced by carrageenin was studied and compared with those of tolfenamic acid. The complex [Zn(tolf)2(H2O)] exhibited the strongest in vivo inhibitory effect at 0.1 mm/kg Body Weight (BW; 93.0±0.9%), superior than the inhibition induced by tolfenamic acid at the same molar dose (76.0±0.9%). Tolfenamic acid and its metal complexes have been evaluated for antiproliferative activity in vitro against the cells of three human cancer cell lines, MCF-7 (breast cancer cell line), T24 (bladder cancer cell line), and A-549 (non-small cell lung carcinoma), and a mouse fibroblast L-929 cell line. The complexes [Mn(tolf)2(H2O)2] and [Cu-(tolf)2(H2O)]2 have shown selectivity against T24 cell line. The IC50 values of these two complexes against T24 cancer cell lines are in a micromolar range similar or better to that of the antitumor drug cisplatin.
Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3
Ma, Shumeng,Zhu, Longqing,Fan, Xiaohong,Luo, Tian,Liu, Dan,Liang, Ziyi,Hu, Xiaoling,Shi, Tao,Tan, Wen,Wang, Zhen
, (2020/12/02)
The combination between two well-studied bioactive compounds melatonin and salicylic acid with proper modifications unexpectedly creates a sharp pair of “scissors” cutting off the vicious connection between inflammation and cancer by targeting a key contributor Signal Transducers and Activators of Transcription 3 (STAT3) in the two pathological processes. A representative compound P-3 with IC50 values on each tested cell line ranging from 7.37 to 18.62 μM among the designed melatonin derivatives is equipped with the ability of curbing inflammation-promoting cancer by down-regulating the expression, activation and nuclear translocation of STAT3, breaking the feedforward loop of STAT3 activation by decreasing the expression of pro-tumorigenic cytokines, and inducing cell apoptosis through ROS triggered Cyto-c/Caspase-3 pathway. This study suggests that the melatonin derivative P-3 is likely to become a promising chemical structure for developing the novel anti-cancer agents taking effect through hindering the mutual-promoting processes between inflammation and cancer.
OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE
-
Page/Page column 199, (2019/06/05)
Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.
